Search for: "Impax Laboratories, Inc."
Results 1 - 20 of 38
Sorted by Relevance | Sort by Date
8 Oct, 2008 4:56 am
... not anticipate claims 1-5 of U.S. Patent No. 5,527,814. The '814 patent, which is owned by Defendant-Appellee Aventis Pharmaceuticals Inc., relates to the use of riluzole to
treat amyotrophic lateral sclerosis (ALS), otherwise known as Lou Gehrig's disease. Aventis markets riluzole under the trade name RILUTEK. Seeking approval to market a generic version
of riluzole, Plaintiff-Appellant Impax Laboratories, Inc. filed an Abbreviated...
14 Dec, 2006 6:47 am
Proof of efficacy is not required for a prior art reference to be enabling for purposes of anticipation. (Fed. Cir. 2006, 05-1313) Impax had
originally filed an ANDA with the FDA seeking approval to market generic riluzole (6-trifluoromethoxy-2-benzothiazolamine) tablets for the treatment of ALS and prompting a suit for a
declaratory judgment that Impax did not infringe, induce [...]
23 Jul, 2008 9:08 pm
The following is excerpted from a July 22, 2008 IMPAX press release at Business Wire: IMPAX
Laboratories, Inc. today announced Boehringer Ingelheim Pharmaceuticals Inc. ("Boehringer") and Astellas Pharma Inc. ("Astellas") have ... for tamsulosin
hydrochloride capsules (0.4 mg), generic of Flomax®, to the Food and Drug Administration. In connection with this ANDA, IMPAX provided notice
to Boehringer and Astellas that its submission includes a Paragraph IV certification stating the Company believes its ...
7 Sep, 2006 6:47 pm
Business Wire reported today, September 7, 2006: IMPAX Laboratories, Inc. (OTC:IPXL) announced that the U.S. Court of Appeals for
the Federal Circuit upheld a lower court ruling in favor of IMPAX in its defense of a lawsuit brought by Alza Corporation, a Johnson &
Johnson (NYSE:JNJ) unit. The suit alleged patent infringement related to IMPAX's filing of an Abbreviated New Drug Application (ANDA) ...
3 Dec, 2008 11:18 pm
By Sherri Oslick -- Earlier this week, Impax Laboratories, Inc. and Medicis Pharmaceutical Corp. announced that they have entered
a Joint Development Agreement and a Settlement and License Agreement that brings to an end their pending lawsuit over Impax's plans to
manufacture a generic version of Medics' Solodyn® (minocycline hydrochloride extended release tablets, used to treat acne). Under the terms of the Agreements, ...
17 Aug 8:01 am
... was a later filer and, therefore, had no eligibility for intellectual property exclusivity. As further compensation, Impax received cash
for promotion of another drug. Given the compression of competition due to the agreement, the FTC ... requesting that it provides information to the FTC relating to its settlement with
Barr and its earlier settlement with Impax Laboratories, Inc. The Company is co-operating fully with this investigation and
believes that the settlements are in compliance with all ...
17 Aug 8:01 am
... was a later filer and, therefore, had no eligibility for intellectual property exclusivity. As further compensation, Impax received cash
for promotion of another drug. Given the compression of competition due to the agreement, the FTC ... requesting that it provides information to the FTC relating to its settlement with
Barr and its earlier settlement with Impax Laboratories, Inc. The Company is co-operating fully with this investigation and
believes that the settlements are in compliance with all ...
17 Nov 10:24 am
... : PLASMA-DERIVATIVE PROTEIN THERAPIES ANTITRUST LITIGATION Motion of plaintiff Hospital Damas, Inc., for centralization of the following actions in the United States District
Court for the Northern District of Illinois: ... ., et al., C.A. No. 1:08-889 Eurand, Inc., et al. v. Impax Laboratories,
Inc., C.A. No. 1:09-18 Eurand, ... National City Mortgage; National City Corp.; PNC Financial Services Group, Inc.; and AIG United Guaranty Corp. for centralization of the
following actions in the United States ...
23 Dec, 2007 8:00 pm
... genome to yield hematopoietic cell lines: (Patent Docs), Wyeth v Impax Laboratories, Inc: 'Extended release formulation' and
other terms defined in ANDA case: ... Law Blog), US International Trade Commission opening investigation into Qualcomm Inc. to determine whether the company is violating a ban on
importing chips that allegedly infringe patents ... Corp: (IP Law360), Sutura's patent infringement suit against Abbot Laboratories regarding suturing technology has come to a
close: (IP Law360), Tiffany v ...
20 Jun, 2007 1:07 am
The East Bay Business Times reported: Abbott Laboratories is suing Impax Laboratories Inc., alleging it infringed on a
patent for the for the bipolar disorder and epilepsy medicine Depakote when filing an application to make a generic version of the drug. Hayward, CA-based Impax announced the suit Tuesday [June 19, 2007], saying it believes its product either does not infringe Abbott's patents or that the listed patents are
invalid.
31 Oct, 2008 6:05 pm
... Impax Laboratories Inc. v. Aventis Pharmaceuticals Inc. (October 3, 2008), the U.S. Court of Appeals for the Federal
Circuit identified eight factors for determining the level ... enable the claimed invention. Minn. Mining & Mfg. Co. v. Chemque, Inc. (3M), 303 F.3d 1294, 1301 (Fed. Cir.
2002). The "undue ... claims, the infringer enjoys a presumption that the anticipating disclosure also enables the claimed invention. Impax
Labs., 468 F.3d at 1382. However, the patentee may overcome that presumption ...
22 Mar 8:52 pm
... will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Warner Chilcott Laboratories Ireland
Ltd. et al. v. Impax Laboratories, Inc. 2:09-cv-01233; filed March 18, 2009 in the ... Modified Release Coated Drug Preparation,"
issued October 25, 2005) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Warner
Chilcott's Doryx® (modified release ...
11 Jan 8:25 pm
... Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.Eurand Inc. et
al. v. Impax Laboratories Inc.1:09-cv-00018; filed January 7, 2009 in the ... Muscle Relaxants," issued July 17, 2008), licensed
to Cephalon, following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Cephalon's Amrix®
(cyclobenzaprine hydrochloride, used for ...
24 Jul 2:29 pm
... then look at 2007. In late October 2006, the District Court decided Wyeth v. Impax Laboratories, Inc., 248 F.R.D. 169 (Oct.
26, 2006), declining to order a native production. Wyeth had made production in TIFF format. Impax filed a motion to compel production in
native format. Because the parties did not agree on a ... Gates on their Electronic Discovery Law blog. In the winter of 2007, in Empire Financial Services, Inc. v. The Bank of
New York, 2007 WL 625899 (Feb. 20, 2007), the Superior ...
18 Nov, 2008 10:40 pm
... the US Food and Drug Administration seeking marketing approval for generic Cymbalta tablets before the expiration of the patent. Lilly also sued Sandoz Inc., Impax Laboratories Inc. and Cobalt Laboratories Inc. in separate lawsuits for seeking generic approval for Cymbalta tablets.
Cymbalta is Lilly's blockbuster drug which exceeded USD 2 billion global sales last year. In separate development, Orion Corporation has filed a ...
6 Apr 7:10 pm
... pharma cases, and a few interesting cases will be selected for periodic monitoring. Genzyme Corp. v. Impax Laboratories, Inc.
1:09-cv-00846; filed April 3, 2009 in the District Court of Maryland Infringement of U.S. Patent No. 5,667,775 ("Phosphate-Binding Polymers for Oral Administration," issued on September
16, 1997) following a Paragraph IV certification as part of Impax's filing of an ANDA to manufacture a generic version of Genzyme's Renvela®
(sevelamer carbonate, used for ...
20 Nov, 2007 12:12 pm
Mich. First Credit Union v. Cumis Ins. Soc'y, Inc., 2007 WL 4098213 (E.D. Mich. Nov. 16, 2007) In May 2007, the court entered an order granting ... , and the Court has not, up to
this point, addressed the discoverability of metadata. In Wyeth v. Impax Laboratories, Inc., 2006 WL 3091331, *2 (D. Del. 2006)
(unpublished), the court stated that "[m] ... D. at 651). Likewise, the Eastern District of Kentucky stated in Kentucky Speedway, LLC v. NASCAR, Inc., 2006 U.S. Dist LEXIS 92028,
*24 (E.D. Ky. 2006), "In ...
23 Sep, 2008 9:34 pm
... ) article, "Wellbutrin Generic to Get New Review", we learned that the FDA is going to re-visit the issues of whether Budeprion XL -- which is made by Impax Laboratories Inc. and distributed by Teva Pharmaceutical Industries Ltd. -- is as safe and effective as Wellbutrin XL -- made by Canada's
Biovail Corp. and sold by GlaxoSmithKline PLC. From the September 23 WSJ article by Andy Georgiades: Five months after declaring a ...
28 Nov, 2006 4:11 pm
... Abbreviated New Drug Application for the sale of riluzole, the district court found that Impax failed to prove the patent as invalid.
Impax Laboratories v. Aventis Pharmaceuticals (05-1313). Riluzole, sold under ... upon underlying factual findings." Minn. Mining &
Mfg. Co. v. Chemque, Inc., 303 F.3d 1294, 1301 (Fed. Cir. 2002). In Amgen, we stated ... did not put one of skill in the art in possession of the invention at all. Elan Pharms.,
Inc. v. Mayo Found., 346 F.3d 1051, 1057 (Fed. Cir. 2003). ...
9 Oct 9:11 am
... : US Philips Corporation v. Samsung Electronics Company Ltd. and Samsung Electronics America Inc. (patent infringement) 9/18: Research Foundation of State University of New
York, New York University, Galderma Laboratories, Galderma Laboratories LP v. Impax Laboratories (patent infringement)
9/18: Ricoh Company Ltd. and Ricoh ... Company v. PLIVA-HRVATSKA d.o.o, PLIVA d.d., Barr Laboratories Inc., Barr Pharmaceuticals Inc., Barr Pharmaceuticals, LLC, et
al. (patent infringement)
Search on: Blawgs.FM | BlawgSearch Google Co-op |
Blawg.com | Bloglines | Feedster | Google Blog Search |
Technorati | Google | MSN | Yahoo!